With a boost from Congress, telehealth can help stop overdose deaths
Credit: The Hill
Telehealth was a game-changer for people struggling with opioid use disorder during the COVID-19 pandemic, with more patients able to start and stay in treatment over the past three years than in previous years.
But unless Congress acts, this critical lifeline to care will disappear.
The Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, a bill before Congress, would allow patients with opioid use disorder to receive a prescription for buprenorphine — a lifesaving medication proven to reduce overdose deaths and help people stay in treatment — by video or audio-only (i.e., telephone) appointments without first being evaluated in person by a health care provider.
Temporary regulations put in place during the pandemic currently allow patients to receive care this way. Unfortunately, these regulations will expire at the end of the year, once again putting lives at risk.
Prior to the pandemic, federal law required health care providers to see patients in person before prescribing buprenorphine. But in March 2020, to encourage physical distancing, the Drug Enforcement Administration allowed providers to prescribe the medication remotely.
As a result, for the past several years patients have been able to access treatment without having to worry about lack of transportation or child care, taking time off work or other circumstances that could affect their access to care. Patients also haven’t had to endure long wait times for appointments or face the stigma and judgment that too often accompany in-person office visits.
Simply put, remote access to buprenorphine has helped save lives. And evidence shows that expanding buprenorphine access via telehealth has been transformative for people with opioid use disorder.
For example, remote prescribing helped close gaps in care for communities with already low treatment rates. Veterans accessing buprenorphine via telehealth were more likely to stay in treatment than those seen in person. More people who lived in remote rural areas or lacked adequate transportation or child care got the care they needed. And Medicare recipients who received telehealth services were more likely to maintain their treatment and less likely to overdose.
Notably, many of these patients received buprenorphine treatment via audio-only visits, which are critical for connecting to treat people without reliable internet access or the technology to conduct video calls. Numerous studies show that audio-only care is as safe, effective and high-quality as audio-video appointments, that patients and providers are satisfied with the care provided and delivered and that patients are no more likely to misuse their prescriptions or give or sell them to another person, a practice known as diversion.
In fact, concerns that remote buprenorphine prescribing could lead to a spike in diversion are unfounded. The Drug Enforcement Administration and the National Institute on Drug Abuse have both stated that expanding access to buprenorphine decreases diversion of the drug. And when it does happen, it’s usually by people unable to access legal treatment who are trying to manage withdrawal symptoms. Importantly, greater access to buprenorphine over the past three years has not led to more buprenorphine-related overdoses.
Medications like buprenorphine are hands down the best way to treat opioid use disorder and curb overdose deaths, but these therapies remain out of reach for too many patients: Barely 1 in 4 people in need of services receive any. Remote access to buprenorphine can help close this treatment gap by removing obstacles to care, but as long as remote prescribing rules remain temporary — and as long as TREATS is not passed — the treatment gap will never fully close.
Health care providers must invest time and resources into setting up remote care, which they may be hesitant to do if telehealth provisions are not here to stay. In one study, addiction providers noted they were reluctant to conduct remote evaluations of patients due to a lack of clarity surrounding the telehealth guidelines and fears about transitioning patients back to in-person care. At the same time, the clinicians offered unanimous support for making the temporary regulations permanent.
The TREATS Act could permanently transform how patients receive opioid use disorder treatment. We thank Reps. Brian Fitzpatrick (R-Pa.) and David Trone (D-Md.), as well as U.S. Sens. Sheldon Whitehouse (D-R.I.), Lisa Murkowski (R-Alaska), Mark Warner (D-Va.) and Marsha Blackburn (R-Tenn.), for their leadership on this legislation, and we urge their colleagues to join them in passing the TREATS Act.
As people with opioid use disorder and their loved ones can attest, lives are at stake, and they can’t afford to go back. Time is running out.